ClinicalTrials.gg
CompletedNCT03542344Updated Nov 28, 2025Results posted

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.

A Phase 1 interventional study of BI 1015550 6 mg and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The primary objective of this trial is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of single rising doses.

Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality of BI 1015550 after single dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 20 to 45 years (incl.) at screening.
  • (BMI) of 18.5 to 25.0 kg/m2 (incl.) at screening.
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) at screening
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance at screening
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders, including but not limited to mood disorders and any history of suicidality
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections including viral hepatitis, (HIV) and/or syphilis. (Subject with positive core antibody will not allowed to participate in this trial)
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (consumption of more 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until three months after the study completion.

Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device or hormonal contraceptive since at least two months)

In addition, the following trial-specific exclusion criteria apply:

  • Positive or missing fecal occult blood (no retest allowed) at screening
  • Positive testing for fecal calprotectin (retest allowed) at screening
  • Positive testing for hematuria if confirmed by microscopic urine analysis (retest allowed) at screening
  • Any lifetime history of suicidal behavior (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BI 1015550 12mg

    Drug: BI 1015550 6 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    BI 1015550 24mg

    Drug: BI 1015550 6 mg

Interventions

  • Single rising oral dose

    Also known as: Nerandomilast, JASCAYD®

  • DrugPlacebo

    Single rising oral dose

06

What researchers measure

Primary outcomes

  1. Number of Participants With Drug-related Adverse Events

    Number of participants with drug-related adverse events is presented.

    Time frame: From drug administration until end of study, up to 9 days

Secondary outcomes

  1. Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

    Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) is presented.

    Time frame: Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.

  2. Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of the BI 1015550 in plasma (Cmax) is presented.

    Time frame: Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.

07

Results

Posted Nov 28, 2025
Limitations and caveats
The planned 36mg dose was not investigated and dose proportionality was not assessed as the pharmacokinetic variables (Cmax and AUC0-inf) would be higher than the predetermined safety margin with 36mg dose based on the interim analysis.

Participant flow

This randomized, parallel, placebo-controlled and double-blind trial tested single dose of BI 1015550 in 2 rising dose groups (12 and 24 mg). Subjects stayed in-house for 2 days (d) after single oral dose of trial drug and the end of trial examination took place 7 to 8 d after trial drug administration.

Participant flow — Overall Study
MilestonePlaceboBI 1015550 12mgBI 1015550 24mg
Started466
Completed466
Not completed000

Outcome measures

PrimaryNumber of Participants With Drug-related Adverse Events

Number of participants with drug-related adverse events is presented.

Time frame:
From drug administration until end of study, up to 9 days
Reported as:
Count of participants · Participants
Number of Participants With Drug-related Adverse Events
ParticipantsPlaceboBI 1015550 12mgBI 1015550 24mg
Number of Participants With Drug-related Adverse Events000
SecondaryArea Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) is presented.

Time frame:
Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.
Reported as:
Geometric mean · nanomole*hours per Litre (nmol*h/L)
Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
nanomole*hours per Litre (nmol*h/L)BI 1015550 12mgBI 1015550 24mg
Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)2410 ± 20.85760 ± 21.6
SecondaryMaximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

Maximum measured concentration of the BI 1015550 in plasma (Cmax) is presented.

Time frame:
Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.
Reported as:
Geometric mean · nanomole per Litre (nmol/L)
Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)
nanomole per Litre (nmol/L)BI 1015550 12mgBI 1015550 24mg
Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)449 ± 19.1944 ± 43.5

Adverse events

Collected over "All-Cause Mortality", "Serious Adverse Events" and "Other Adverse Events": From first drug administration until end-of-study examination, up to 9 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)1/4 (25%)
BI 1015550 12mg0/6 (0%)0/6 (0%)0/6 (0%)
BI 1015550 24mg0/6 (0%)0/6 (0%)0/6 (0%)
BI 1015550 Total0/12 (0%)0/12 (0%)0/12 (0%)
Most frequent other events
Most frequent other events
EventPlaceboBI 1015550 12mgBI 1015550 24mgBI 1015550 Total
Occult blood positiveInvestigations1/40/60/60/12

Baseline characteristics

Treated set (TS): This subject set included data from all subjects who received at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)PlaceboBI 1015550 12mgBI 1015550 24mgTotal
Mean27.5 ± 4.732.8 ± 9.328.7 ± 8.329.9 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBI 1015550 12mgBI 1015550 24mgTotal
Female0000
Male46616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBI 1015550 12mgBI 1015550 24mgTotal
Hispanic or Latino0000
Not Hispanic or Latino46616
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBI 1015550 12mgBI 1015550 24mgTotal
American Indian or Alaska Native0000
Asian46616
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • SOUSEIKAI Sumida Hospital
    Tokyo, Sumida-ku, 130-0004, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Aug 2018, 2 months.

Results were first posted in Nov 2025, 7 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
May 31, 2018
StartActual
Jun 4, 2018
Primary completionActual
Aug 24, 2018
CompletionActual
Aug 24, 2018
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03542344
Responsible party
Sponsor
First posted
May 31, 2018
Start date
Jun 4, 2018
Primary completion
Aug 24, 2018
Completion
Aug 24, 2018
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion